Corporate News

Rameda One-Pager 1Q25

Earnings Release One-Pager 4Q24

Earning Release One Pager 3Q24

Rameda Completes Largest Acquisition to Date

Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Market

Earning Release One Pager 2Q24

Rameda Announces Price Increase Approvals for All Its Top Products

Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance

Rameda 4Q23 Earnings Release

Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic Portfolio

Rameda Reports its 3Q23 Results

Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Rameda Reports its 2Q23 Results

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic products

Rameda Reports its 1Q23 Results

Rameda Reports its FY22 Results

Rameda acquires exclusive rights for the distribution and marketing of “Physiomer” in Egypt

Rameda Reports its 3Q22 Results

Rameda Reports its 3Q22 Results

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. inaugurates a new high-precision water treatment station

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. joins the UN Global Compact, the world’s largest corporate sustainability initiative.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. commences the production of antiviral COVID-19 treatment, Molnupiravir Rameda

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires a fast-growing anticonvulsant which grew at 2019-21 CAGR of 226%

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires fast-growing molecule with an established market presence

Rameda Partners with IFC to Green its Operations in Egypt

Rameda Reports its 1Q22 Results

Rameda Reports its FY22 Results

Equinox Pharma Holding Limited (Equinox), alongside other investors, further increases its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Rameda Reports its FY21 Results

Rameda Reports its 3Q21 Results

Rameda Reports its 2Q21 Results

Equinox Pharma Holding Limited (Equinox) increases its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires a sizeable molecule in a fast-growing therapeutic area

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.’s Chief Executive Officer, Dr. Amr Morsy, recognized among the top 100 Arabian CEOs of 2020

Rameda Reports its 1Q21 Results

Rameda Reports its FY20 Results

Rameda Reports its 3Q19 Results

Rameda Reports its 3Q20 Results

Rameda Reports its 2Q20 Results

Rameda notified of Anviziram, Remdesivir-Rameda vial prices by Egyptian Drug Authority, on track to market first Remdesivir-Rameda production in September 2020

Rameda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir

Rameda Reports its 1Q20 Results

Rameda values the role played by the Egyptian Pharmacists Syndicate and Pharmacies in serving patients across Egypt

Rameda issues statement regarding the “Stay Home to Protect your Family and Community” initiative

Rameda launches initiative for the complementary dispensary and home delivery of medication at no cost, underlining its dedication to ensuring the healthcare and safety of some of Egypt’s most immune-compromised patient populations amid the COVID-19 pandemic

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Acquires A Large Generic Product in a Sizable and Fast-Growing Therapeutic Area

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Reports double-digit topline growth in FY19 and major facility upgrades & expansions completed during the year

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Announced Indicative Results for FY2019

Rameda shares begin trading on Egyptian Exchange

Rameda Reports its 3Q19 Results

Rameda announces the fixed offer price of its IPO on EGX

Rameda announces its intention to float on the Egyptian Exchange